Athernal Bio
United Kingdom · Biotech
Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges.
Intervene at a cancer precursor stage
Athernal is developing immunotherapies for clonal haematopoiesis, a condition in which mutated blood stem cells expand and can raise the risk of acute myeloid leukaemia and other blood cancers. Its approach is to target high-risk pre-malignant cell populations before a fully established cancer requires treatment.
The lead program, ath-001, is aimed at rare inherited blood disorders associated with accelerated clonal haematopoiesis and AML risk; a second program addresses therapy-induced clonal haematopoiesis in cancer survivors. Both remain in development, with the company advancing early-stage research toward clinical testing.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Grant | ~£700K | Innovate UK — Participant |